TipRanks
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
US Market
CNTB
Connect Biopharma Holdings
RESEARCH TOOLSreports
Want to see CNTB full AI Analyst Report?

Connect Biopharma Holdings (CNTB) Stock Forecast & Price Target

231 Followers
See the Price Targets and Ratings of:

CNTB Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Connect
Biopharma Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CNTB Stock 12 Month Forecast

Average Price Target

$6.86
▲(179.88% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Connect Biopharma Holdings in the last 3 months. The average price target is $6.86 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 179.88% change from the last price of $2.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.857142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.979,1.672923076923077,2.366846153846154,3.060769230769231,3.754692307692308,4.448615384615385,5.142538461538462,5.836461538461539,6.530384615384616,7.2243076923076925,7.91823076923077,8.612153846153847,9.306076923076922,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.979,1.4311648351648352,1.8833296703296702,2.3354945054945055,2.7876593406593404,3.2398241758241757,3.691989010989011,4.144153846153846,4.596318681318681,5.0484835164835165,5.500648351648351,5.952813186813186,6.404978021978022,{"y":6.857142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.979,1.2113846153846153,1.4437692307692307,1.676153846153846,1.9085384615384615,2.1409230769230767,2.373307692307692,2.6056923076923075,2.838076923076923,3.0704615384615384,3.3028461538461538,3.535230769230769,3.7676153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.979,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$6.86Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CNTB
Will Soghikian
Leerink Partners
Leerink Partners
$4
Buy
63.27%
Upside
Initiated
10/12/26
Leerink Partners Sticks to Their Buy Rating for Connect Biopharma Holdings (CNTB)
H.C. Wainwright Analyst forecast on CNTB
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$7
Buy
185.71%
Upside
Reiterated
10/08/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Connect Biopharma Holdings (NASDAQ: CNTB) and Helus Pharma (NASDAQ: HELP)
Canaccord Genuity Analyst forecast on CNTB
Edward Nash
Canaccord Genuity
Canaccord Genuity
$6
Buy
144.90%
Upside
Reiterated
10/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Lake Street Analyst forecast on CNTB
Thomas Flaten
Lake Street
Lake Street
$9
Buy
267.35%
Upside
Reiterated
10/01/26
Lake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)
Oppenheimer Analyst forecast on CNTB
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$8→$5
Buy
104.08%
Upside
Assigned
09/22/26
Connect Biopharma price target lowered to $5 from $8 at OppenheimerConnect Biopharma price target lowered to $5 from $8 at Oppenheimer
BTIG Analyst forecast on CNTB
Julian Harrison
BTIG
BTIG
$10
Buy
308.16%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (NASDAQ: CNTB) and Stryker (NYSE: SYK)
Piper Sandler Analyst forecast on CNTB
Biren Amin
Piper Sandler
Piper Sandler
$7
Buy
185.71%
Upside
Reiterated
08/13/26
Piper Sandler Reaffirms Their Buy Rating on Connect Biopharma Holdings (CNTB)
Cantor Fitzgerald Analyst forecast on CNTB
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$4
Buy
63.27%
Upside
Initiated
05/21/26
Connect Biopharma initiated with an Overweight at Cantor FitzgeraldConnect Biopharma initiated with an Overweight at Cantor Fitzgerald
Northland Securities Analyst forecast on CNTB
Carl Byrnes
Northland Securities
Northland Securities
$7.5
Buy
206.12%
Upside
Reiterated
04/24/26
Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CNTB
Will Soghikian
Leerink Partners
Leerink Partners
$4
Buy
63.27%
Upside
Initiated
10/12/26
Leerink Partners Sticks to Their Buy Rating for Connect Biopharma Holdings (CNTB)
H.C. Wainwright Analyst forecast on CNTB
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$7
Buy
185.71%
Upside
Reiterated
10/08/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Connect Biopharma Holdings (NASDAQ: CNTB) and Helus Pharma (NASDAQ: HELP)
Canaccord Genuity Analyst forecast on CNTB
Edward Nash
Canaccord Genuity
Canaccord Genuity
$6
Buy
144.90%
Upside
Reiterated
10/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Lake Street Analyst forecast on CNTB
Thomas Flaten
Lake Street
Lake Street
$9
Buy
267.35%
Upside
Reiterated
10/01/26
Lake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)
Oppenheimer Analyst forecast on CNTB
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$8→$5
Buy
104.08%
Upside
Assigned
09/22/26
Connect Biopharma price target lowered to $5 from $8 at OppenheimerConnect Biopharma price target lowered to $5 from $8 at Oppenheimer
BTIG Analyst forecast on CNTB
Julian Harrison
BTIG
BTIG
$10
Buy
308.16%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (NASDAQ: CNTB) and Stryker (NYSE: SYK)
Piper Sandler Analyst forecast on CNTB
Biren Amin
Piper Sandler
Piper Sandler
$7
Buy
185.71%
Upside
Reiterated
08/13/26
Piper Sandler Reaffirms Their Buy Rating on Connect Biopharma Holdings (CNTB)
Cantor Fitzgerald Analyst forecast on CNTB
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$4
Buy
63.27%
Upside
Initiated
05/21/26
Connect Biopharma initiated with an Overweight at Cantor FitzgeraldConnect Biopharma initiated with an Overweight at Cantor Fitzgerald
Northland Securities Analyst forecast on CNTB
Carl Byrnes
Northland Securities
Northland Securities
$7.5
Buy
206.12%
Upside
Reiterated
04/24/26
Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HROWHarrow Health
KURAKura Oncology
DNLIDenali Therapeutics
STOKStoke Therapeutics
CELCCelcuity
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Connect Biopharma Holdings

3 Months
Brandon FolkesH.C. Wainwright
Success Rate
5/13 ratings generated profit
38%
Average Return
+2.12%
Copying Brandon Folkes's trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of +2.12% per trade.
1 Year
Brandon FolkesH.C. Wainwright
Success Rate
3/13 ratings generated profit
23%
Average Return
-19.76%
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -19.76% per trade.
2 Years
Edward NashCanaccord Genuity
Success Rate
0/5 ratings generated profit
0%
Average Return
-51.86%
Copying Edward Nash's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -51.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTB Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
15
13
13
14
17
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
13
13
14
17
In the current month, CNTB has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CNTB average Analyst price target in the past 3 months is 6.86.
Each month's total comprises the sum of three months' worth of ratings.

CNTB Financial Forecast

CNTB Earnings Forecast

Next quarter’s earnings estimate for CNTB is -$0.26 with a range of -$0.32 to -$0.19. The previous quarter’s EPS was -$0.27. CNTB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CNTB has Performed in-line its overall industry.
Next quarter’s earnings estimate for CNTB is -$0.26 with a range of -$0.32 to -$0.19. The previous quarter’s EPS was -$0.27. CNTB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CNTB has Performed in-line its overall industry.

CNTB Sales Forecast

Next quarter’s sales forecast for CNTB is $773.58K with a range of $0.00 to $5.01M. The previous quarter’s sales results were $2.77M. CNTB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CNTB has Performed in-line its overall industry.
Next quarter’s sales forecast for CNTB is $773.58K with a range of $0.00 to $5.01M. The previous quarter’s sales results were $2.77M. CNTB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CNTB has Performed in-line its overall industry.

CNTB Stock Forecast FAQ

What is CNTB’s average 12-month price target, according to analysts?
Based on analyst ratings, Connect Biopharma Holdings’s 12-month average price target is 6.86.
    What is CNTB’s upside potential, based on the analysts’ average price target?
    Connect Biopharma Holdings has 179.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CNTB a Buy, Sell or Hold?
          Connect Biopharma Holdings has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Connect Biopharma Holdings’s price target?
            The average price target for Connect Biopharma Holdings is 6.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 179.88% Increase from the current price of $2.45.
              What do analysts say about Connect Biopharma Holdings?
              Connect Biopharma Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CNTB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.